BIOGEN INC. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
BIOGEN INC. (BIIB) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $74.70 million as of 2025-12-31, per its 10-K filed 2026-02-06.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-02-06
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $74.70M.
- 2024-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $83.80M.
- 2023-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $101.40M.
- 2022-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $40.10M.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2025-12-31 | $74.70M 10-K · filed 2026-02-06 |
| 2024-12-31 | $83.80M 10-K · filed 2025-02-12 |
| 2023-12-31 | $101.40M 10-K · filed 2024-02-14 |
| 2022-12-31 | $40.10M 10-K · filed 2023-02-15 |
| 2021-12-31 | $35.50M 10-K · filed 2022-02-03 |
| 2020-12-31 | $47.80M 10-K · filed 2021-02-03 |
| 2019-12-31 | $58.30M 10-K · filed 2020-02-06 |
| 2019-09-30 | $61.30M 10-Q · filed 2019-10-22 |
| 2019-06-30 | $64.90M 10-Q · filed 2019-07-24 |
| 2019-03-31 | $68.60M 10-Q · filed 2019-04-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |